EX-10.5



 Exhibit 10.5 

CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.—CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION. 
 132965/MG/CP 

RESEARCH, PRODUCT DEVELOPMENT, OPTION, LICENSE 

AND COMMERCIALIZATION AGREEMENT 

BETWEEN 
 LES
LABORATOIRES SERVIER SAS 
 INSTITUT DE RECHERCHES INTERNATIONALES SERVIER SAS 

AND 
 CELLECTIS SA


  
 1/44 








 PRODUCT DEVELOPMENT, OPTION, LICENSE AND COMMERCIALIZATION AGREEMENT 

This Product Development, Option, License and Commercialization Agreement shall become effective as of the 17 day of February, 2014 (the “Effective
Date”) by and between Les Laboratoires Servier, a corporation incorporated under the laws of France having a principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and lnstitut de Recherches
lnternationales Servier, a corporation incorporated under the laws of France having its principal place of business at 50 rue Carnot, 92 150 Suresnes, France (“IRIS”) (LLS and IRIS being together referred to as “Servier”),
and Cellectis SA, a company incorporated under the laws of France having a principal place of business, at 8, rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Cellectis and Servier are individually referred to herein as a
“Party” and collectively, as the “Parties.” 
 RECITALS 

WHEREAS, Cellectis has developed, owns or otherwise Controls (as hereinafter defined) certain intellectual property and know-how regarding the
engineering of primary cells (e.g. T-cells) for therapeutic applications in the field of anti-tumor adoptive immunotherapy. 

WHEREAS, Servier possesses research, development, manufacturing and commercialization expertise for the development and commercialization of
pharmaceutical products in the field of oncology. 
 WHEREAS, Servier wishes Cellectis, and Cellectis accepts, to perform development activities up
to and including Phase I of certain of the Candidate Product(s) selected by Servier. 
 WHEREAS, Servier wishes to have the exclusive option to get
an exclusive worldwide licence over certain Product(s) it may wish to select in order to further develop, promote and commercialize them, as specified in the Agreement. 

Now, therefore, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties agree as follows: 
  

	ARTICLE 1.	DEFINITIONS. 

 The following capitalized terms or derivatives thereof (verbs, nouns, singular, plural),
when used in this Agreement, will have the following meanings: 
 1.1. “Affiliates” means with respect to a Party, any person or entity,
whether de jure or de facto, which directly or indirectly controls, is controlled by, or is under common control with such Party. Solely as used in this definition, the term “control” means (i) the ownership, directly or indirectly,
beneficially or legally, of at least fifty percent (50%) of the outstanding voting securities or capital stock (or such lesser percentage which is the maximum allowed to be owned by a person or entity in a particular jurisdiction) of such Party
or other person or entity, as applicable, or such other comparable ownership interest with respect to any person or entity that is not a corporation; or (ii) the possession, directly or indirectly of the power, whether pursuant to contract,
ownership of securities or otherwise, to direct the management and policies of a Party or such other person or entity, as applicable. 

  
 2/44 








 1.2. “Agreement” means this Product Development, Option, License and Commercialization Agreement
together with the recitals and all exhibits, schedules and attachments hereto. 
 1.3. “Attribute” means a particular genome modification
obtained by nucleases or any other methods, including without limitation knock out, knock in and point mutations. 
 1.4. “Background IP”
means Patents and Know How Controlled by a Party prior to the Effective Date and/or developed or acquired by such Party during, but outside of, this Agreement 

1.5. “Backup Product” [***]. 
 1.6.
“Candidate Product” means an allogenic anti-tumor adoptive T-cell expressing a single chain chimeric antigen receptor (CAR) directed against a particular Target including specific Attributes selected by Servier according to
Section 3.2(c). Except for section 6.3., Candidate Product also applies to a Backup Product and/or a Follow-on Product in case of application of Section 3.4. 

1.7. “Cellectis IP” means any and all Cellectis Patent(s) and Know-How developed and/or Controlled by Cellectis and its Affiliates before the
Effective Date or thereafter during the Term, that is necessary or useful for the Development, Manufacture and Commercialization of a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate. For avoidance of doubt Cellectis IP shall
include Cellectis’ interest in the Joint Intellectual Property. 
 1.8. “Cellectis Know-How” means all Know-How that is developed or
Controlled by Cellectis at the Effective Date and thereafter during the Term and (i) that results from Cellectis’ activities with respect to the Development or (ii) is reasonably necessary or useful for the Development, Manufacture
and/or Commercialization of a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate. 
 1.9. “Cellectis Knowledge” means
the knowledge, at the Effective Date that Cellectis has after due inquiry. 
 1.10. “Cellectis Patent” means all Patents that are
Controlled by Cellectis and its Affiliates at the Effective Date and thereafter during the Term and that Cover, or would be reasonably necessary or useful for, the Development, Manufacture or Commercialization of Pre-Candidate Product(s), Candidate
Product(s), or Product(s), as appropriate,) (including its composition, formulation, combination, product by process, or method of use, manufacture, preparation or administration). Cellectis Patents shall include Cellectis’ interest in Joint
Patent that meet the above requirements, and in any event shall include those Patents set forth on Exhibit 2. 
 1.11. “Change of Control”
means, with respect to Cellectis, the occurrence of any of the following events: (i) any Third Party begins to control (under the meaning of “control” set forth in Section 1.2 (“Affiliate”)) Cellectis, directly or
indirectly, by any means (including acquisition of shares, share exchange or share transfer); or (ii) Cellectis conveys, transfers, divests or leases (including general succession and all types of corporate split) in one or more transactions to
any Third Party either: (x) all or substantially all of the assets of Cellectis or (y) all or substantially all of its assets that are material to the purpose of performance of its obligations under this Agreement. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 3/44 








 1.12. “Claim” means any charge, complaint, action, suit, proceeding, hearing, investigation,
claim or demand, including without limitation any investigation by a Governmental Authority. 
 1.13. “Clinical Development” means any and
all Development activities performed by a Party following the achievement of animal in vivo proof of concept Milestone. 
 1.14.
“Commercialization” means with respect to a Product any and all activities of marketing, promoting, distributing, importing, offering for sale, having sold and/or selling such Product in the Field in the Territory, including without
limitation defining pricing and reimbursement strategy and approval and pre-launch marketing strategy. 
 1.15. “Commercially Reasonable
Efforts” means, [***]. 
 1.16. “Competent Authority” means any court, tribunal, regulatory agency of (a) any
national, federal, state, provincial, county, city or other political subdivision government, including the FDA, (b) any supranational body (including the EMA). 

1.17. “Competent Authority Approval” means any and all approvals, licenses, registrations or authorizations by a Competent Authority and
necessary for the Development activities (including without limitation any applicable pricing, final labeling and reimbursement approvals of such Governmental Authority), and any MAA or equivalent. 

1.18. “Control”, “Controlled” or “Controlling” means, with respect to a subject item, the ability of a Party, whether
arising by ownership, possession or pursuant to a license or sublicense, to grant licenses or sublicenses to another Party with respect to such subject item, as provided in this Agreement, without violating the terms of any agreement or other
arrangement with any Third Party. 
 1.19. “Cover” “Cover”, “Covered” or “Covering” means, with respect to a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate, and a Patent, that, in the absence of a (sub)license under, or ownership of, such Patent, the making, using, offering for sale, selling or
importing of such a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate, with respect to a given country, would infringe a Valid Claim of such Patent. 

“Data” means any and all research, pharmacology, medicinal chemistry, pre-clinical, clinical, commercial, marketing, process development,
manufacturing and other data or information, including investigator brochures and reports (both preliminary and final), statistical analyses, expert opinions and reports, and safety data, in each case generated from clinical Studies or non-clinical
studies, research or testing specifically related or directed to the Pre-Candidate Product(s), the Candidate Product(s) or Product(s). 
 1.20.
“Development” means with respect to a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate and on a Targeted Indication and Targeted Territory basis, the activities, including the Preclinical Development as well as
the Clinical Development, performed by a Party as from the beginning of the work on a Pre-Candidate Product until and including the MAA filing for the relevant Product, including without limitation: activities related to research, process
development and manufacturing, pre- clinical and clinical drug development of such Candidate Product and/or Product in its Targeted Indication in the Field and in its Targeted Territory, including without
limitation, test method development and stability testing, assay development, toxicology, pharmacology, formulation, quality assurance, quality development, technology transfer, statistical analysis, process development, and scale-up,
pharmakocinetic  

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 4/44 








 
studies, data collection and management, clinical studies (including research to design clinical studies), regulatory affairs (including all necessary steps to Develop the Candidate Product
and/or Product as an orphan drug, obtaining scientific advices), project management, drug safety surveillance activities related to clinical studies, validation of methods and tests. “Development Plan” means, for each Candidate
Product or Product, a working document describing the Targeted lndication(s), Targeted Territories, expected timelines, the preclinical, clinical, manufacturing, regulatory, as well as Candidate Product risk assessment planned activities up to the
issuance of the Phase 1 Data Package by Cellectis to Servier. The JRDC may propose from time to time amendment to the Development Plan that shall be submitted to the JSC for validation as the circumstances may require and subject to
Section 3.3. 
 1.21. “Executive Officer” means the Chief Executive Officer of Cellectis and the Chief Executive Officer of Servier,
or their duly authorized respective designees with equivalent decision-making authority with respect to matters under this Agreement. 
 1.22.
“Field” means the anti-tumor adoptive immunotherapy. 
 1.23. “First Commercial Sale” means the first sale in the Territory
to a Third Party of the Product by or under the authority of Servier or its Affiliate or sublicensees after receipt of the applicable regulatory approval from the Competent Authority(ies). 

1.24. “Follow-on Product” [***]. 

1.25. “Servier Foreground IP” means, with respect to a Product, the part of the Foreground IP that is specifically and solely related to a
Product for which an Option to License has been exercised by Servier according to Section 4.1. 
 1.26. “Good Manufacturing Practices
(cGMP)” means (i) EC Directive 2003/94/EEC as amended from time to time and all the relevant associated detailed guidelines; (ii) the current principles and guidelines of Good Manufacturing Practice for medicinal products for
human use as required by, but not limited to, the applicable sections of the US Federal Food, Drug and Cosmetic Act, the US Public Health Service Act, the US Code of Federal Regulations, Title 21, Parts 210 (Current Good Manufacturing Practice in
Manufacturing, Processing, Packing or Holding of Drugs; General), and relevant US Food and Drug Administration Guidance and Points to Consider for drugs and/or biotechnology-derived products, as amended from time to time; and (iii) the
equivalent current law or regulation in any market. 
 1.27. “In Vitro Data Package” [***]. 

1.28. “In-Vivo Milestone” [***]. 

1.29. “Joint Intellectual Property” or “Joint IP” means all intellectual property rights in Joint Inventions (which for the
avoidance of doubt shall include Joint Know-How and Joint Patent). 
 1.30. “Joint lnvention(s)” means an invention arising during the Term
that is jointly created by one or more employees, consultants, or contractors of each Party or of any Affiliate or sublicensee of such Party in the course of performing activities under this Agreement. 

1.31. “Joint Know-How” means all Know-How arising during the Term that is jointly created by one or more employees, consultants, or
contractors of each Party or of any Affiliate of such Party in the course of performing activities under this Agreement. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 5/44 








 1.32. “Joint Patent” means a Patent that claims a Joint Invention. 

1.33. “Know-How” means all technical information, techniques, data, database rights, discoveries, inventions, practices, methods, knowledge,
skill, experience, test data or information necessary for the discovery, development, manufacture use, sale or commercialization of a Pre-Candidate Product, a Candidate Product, or a Product, as appropriate. 

1.34. “MAA” means, in relation to any Product, an application filed or to be filed with the European Medicines Agency (or equivalent national
agency), for authorization to place a medicinal product on the market in the European Union (or any other territory). 
 1.35. “Manufacture”
means with respect to a Pre-Candidate Product, a Candidate Product or a Product, any and all processes and activities conducted to manufacture preclinical, clinical and commercial quantities of such, in particular, the production, the
manufacture, the processing, the filling, the packaging, the labeling, the inspection and the shipping of such Pre-Candidate Product, Candidate Product or Product. Manufacture shall also include the supply of any raw materials or packaging materials
with respect thereto, or any intermediate of any of the foregoing, including process and cost optimization, process qualification and validation, commercial manufacture, stability and release testing, quality assurance and quality control. For
clarity, “Manufacturing” has a correlative meaning. 
 1.36. “Manufacturing process validation” [***]. 

1.37. “Milestone Data” means any information and results supporting the achievement of a Milestone. 

1.38. “Net Revenues” [***]. 
 1.39.
“Net Sales” [***]. 
 1.40. “Option Date” shall mean the date at which the Option to License over a particular Product
is exercised by Servier pursuant to Section 4.1 (b). 
 1.41. “Patent” means (a) issued patent, including any extension,
registration, confirmation, reissue, continuation, supplementary protection certificate, divisional, continuation-in-part, re-examination or renewal thereof, (b) pending applications for all of the
foregoing, and (c) foreign counterparts of any of the foregoing; in each case to the extent the same has not been held, by a court of competent jurisdiction, to be invalid or unenforceable in a decision from which no appeal can be taken or from
which no appeal was taken within the time permitted for appeal. 
 1.42. “Phase 1” means first time in human clinical trial in the first
indication. 
 1.43. “Phase 1 Data Package” [***]. 

1.44. “Pre-Candidate Product” means an allogenic anti-tumor adoptive T-cell expressing a single chain chimeric antigen receptor (CAR)
directed against a particular Target including specific Attributes. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 6/44 








 1.45. “Preclinical Development” means any and all non-clinical Development activities performed
by a Party until and including animal in vivo Proof of Concept Milestone. 
 1.46. “Product” means a Candidate Product selected by Servier
according to Section 4.1(b). Except for sections 6.2. and 6.3, Product also means a Backup Product and/or a Follow-on Product. 
 1.47.
“Program” means the Development activities performed by Cellectis relating to a particular Pre-Candidate Product and Candidate Product up to and including Phase 1, as described in Exhibit 1 for
the UCART19 Product, and as described in a separate document provided by the JRDC as per Section 3.2(b) for the other Pre-Candidate Product and Candidate Product(s). 

1.48. “Program Term” means the duration of each Program. 

1.49. “Royalty Term” means on a country-by-country basis and Product-by-Product basis, the period commencing on the First Commercial Sale of
a Product in a country and ending on the latest of (a) expiration of the last-to-expire Valid Claim of a Cellectis Patent that Covers such Product in such country or (b) the expiration of the Regulatory Exclusivity Rights with respect to
such Product in such country. 
  1.50. “Servier IP” means any and all Servier Patent(s) and Know-How developed and/or Controlled by
Servier and its Affiliates after the Effective Date that is necessary or useful for the discovery, development, manufacture, use, sale or commercialization of a Pre-Candidate Product, a Candidate Product or a
Product, as appropriate. For avoidance of doubt Servier IP shall include Servier’ interest in the Joint Intellectual Property. 
  1.51.
“Servier Know-How” means all Know-How that is developed or Controlled by Servier after the Effective Date and thereafter during the Term and (i) that results from Servier’s activities with respect to the Development or
(ii) is reasonably necessary or useful for the Development, manufacture, and/or Commercialization of a Pre-Candidate Product, a Candidate Product or a Product, as appropriate. 

1.52. “Servier Patent” means all Patents that are Controlled by Servier and its Affiliates after the Effective Date and thereafter during the
Term and that Cover, or would be reasonably necessary or useful for, the Development, manufacture or Commercialization of the Pre-Candidate Product(s), Candidate Product(s) or the Product(s) (including its composition, formulation, combination,
product by process, or method of use, manufacture, preparation or administration). Servier’s Patents shall include Servier’s interest in Joint Patent that meet the above requirements. 

1.53. “TAL nuclease” means an artificial restriction enzyme consisting of one or more polypeptides that comprise a sequence from a
transcription activator-like effector protein designed to recognize and cleave a recognition site in a target sequence, engineered and sold by Cellectis or its Affiliates in the framework of this Agreement. [***]. 

1.54. “Target” means an antigen expressed on the cell surface of a tumor cell proposed by Cellectis to Servier and/or by Servier to Cellectis
through the JRDC and approved by the JSC, all before the beginning of the implementation of each Program by Cellectis. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 7/44 








 1.55. “Targeted Indication” means with respect to a Pre-Candidate Product, a Candidate Product
or a Product, the therapeutic indication determined in such Product’s Development Plan, and within the Field. 
 1.56. “Targeted
Territory” means with respect to each Pre-Candidate Product, Candidate Product or Product, the following country(ies) or region(s): [***]. 

1.57. “Term” will have the meaning assigned to such term in Section 11.1. 

1.58. “Territory” means any and all countries of the world. 

1.59. “Third Party” means any person or entity other than Cellectis, Servier or an Affiliate of Cellectis or Servier. 

1.60. “UCART19 Product” [***]. 
 1.61.
“Valid Claim” means a claim of an issued and unexpired patent or patent application included in a Patent, which claim has not been revoked or held invalid or unenforceable by a court or other government agency of competent jurisdiction
or has not been held or admitted to be invalid or unenforceable through re-examination or disclaimer, reissue, opposition procedure, nullity suit or otherwise. Notwithstanding the foregoing, if a claim of a pending patent application within a Patent
has not issued as a claim of a patent within [***] after the filing date from which such claim takes priority, such claim shall not be a Valid Claim for the purposes of this Agreement, unless and until such claim issues as a claim of any issued
patent (from and after which time the same would be deemed a Valid Claim subject to the first sentence of the definition above). With respect to a claim of a pending patent application, the phrase to “infringe a Valid Claim” shall mean to
engage in activity that would infringe such claim if it were contained in an issued patent. 
  

	ARTICLE  2.	MANAGEMENT 

 2.1. Overview. Promptly after the Effective Date, the Parties shall establish three
(3) committees which shall manage the collaboration between the Parties until the exercise (or non-exercise) of the Option to License by Servier as indicated in section 4.1 hereafter. 

2.2. Alliance Managers. Each of Servier and Cellectis shall appoint one or two senior representatives who possess a general understanding of
development, regulatory, manufacturing and commercialization matters to act as its respective alliance manager(s) for this relationship (each, an “Alliance Manager”). Each Party may replace its respective Alliance Manager(s) at any time
upon written notice to the other in accordance with this Agreement. Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager. Each Alliance Manager shall be charged with creating and maintaining a
collaborative work environment within and among the Committees. Consistent with the Development Plan and Section 2.10, each Alliance Manager, on behalf of the applicable Party’s Co-Chairperson of the applicable Committee, will also be
responsible for: 
  

	 	(a)	providing a primary single point of communication responsible for the flow of communication and for seeking consensus both within the respective Party’s organization and together regarding key strategy and plan
issues; 


  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 8/44 









	 	(b)	ensuring that the governance procedures and rules set forth herein are complied with 

  

	 	(c)	identifying and raising disputes to the JSC or JEC for discussion in a timely manner; and 

  

	 	(d)	planning and coordinating internal and external communications in accordance with the terms of this Agreement. 


The Alliance Managers shall be entitled to attend all JRDC, JSC and JEC meetings, and shall have the right to attend all Subcommittees meetings. Consistent
with Section 2.10, each Alliance Manager may bring any matter to the attention of the JSC or JEC where such Alliance Manager reasonably believes that such matter requires attention of the JSC or JEC. 

At the latest ten (10) days after the Effective Date, each Party shall appoint and notify the other Party of the identity of their representatives to act
as alliance managers under this Agreement. 
 2.3. Project Directors. Within ten (10) days following the Effective Date each Party shall appoint
and notify the other Party of the identity of a representative to act as its project director (“Project Director”). The Project Director shall be responsible for the follow-up of the Development activities under this Agreement on a regular
basis. The Project Director may attend the meetings of the JSC, as requested by the Co- Chairperson. Each Party may replace its Project Director upon written notice to the other Party. 

2.4. Joint Executive Committee (the “JEC”). 

2.4.1. Composition. The JEC shall be comprised of up to two (2) senior executives from each Party. Promptly following the Effective Date, each
Party shall designate by written notice to the other Party its initial representatives on the JEC. Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change.
Either Party may, from time to time, invite additional representatives or consultants to attend JEC meetings, subject to such representative’s and consultant’s written agreement to comply with confidentiality obligations substantially the
same as those set forth in article 8. 
 2.4.2. Function and Powers of the JEC. The JEC shall: (a) manage the overall collaboration between the
Parties and manage resource allocation and major changes to the collaboration requiring amendments to this Agreement, (b) resolve disputed matters that may arise at the JSC, in accordance with Section 2.10, (c) draw up an annual
review of implementation of the Collaboration and performance of the Agreement. 
 2.4.3. Frequency of Meetings. The Joint Executing Committee shall
meet annually, and in no event less than once annually and such meetings may be conducted by telephone, videoconference or in person as determined by the Co-Chairpersons. As appropriate, provided that not less than two (2) Business Days’
prior written notice has been given to the other Party, and subject to such other Party’s approval (not to be unreasonably withheld, delayed or retained), other employees of the Parties may attend Joint Executive Committee meetings as
observers. Either Party may also call a special meeting of a Joint Executive Committee (in person, by videoconference or teleconference) by at least ten (10) Business Days’ prior written notice to the other Party in the event such Party
reasonably believes that a significant matter 

  
 9/44 








 
must be addressed prior to the next regularly scheduled meeting, and such Party shall provide the Joint Executive Committee no later than ten (10) Business Days prior to the special meeting
with materials reasonably adequate to enable an informed decision. 
 2.5. Joint Steering Committee (the “JSC”). 

2.5.1. Composition. The JSC shall be comprised of three (3) named representatives of each Party (or such other number as the Parties may agree) in
addition to each Party’s Alliance Manager who are members ex-officio. Promptly following the Effective Date, each Party shall designate by written notice to the other Party its initial representatives on the JSC. Each Party may replace one or
more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change. Either Party may, from time to time, invite additional representatives or consultants to attend JSC meetings, subject to such
representative’s and consultant’s written agreement to comply with confidentiality obligations substantially the same as those set forth in article 8. 

2.5.2. Function and Powers of the JSC. The JSC shall: (a) review and approve the Development Plan and the associated budget and any annual or
interim updates and proposed amendments thereto; (b) direct and oversee the JRDC on all significant issues; (c) review and approve the recommendations of the JRDC; (d) with respect to each Program, to validate the criteria of success
of each Milestone proposed by the JRDC (the “Criteria of Success”) and the achievement of each Milestone, provided that such validation shall be deemed reached if the corresponding Milestone Data meet the corresponding Criteria of Success;
(e) shall have overall responsibility for the oversight of the performance of the Clinical activities for each Program; (f) direct and oversee any operating subcommittee on all significant issues; (g) validate and back-up the
intellectual property strategy; (h) resolve disputed matters that may arise at the JRDC and the subcommittees, in accordance with Section 2.10, and (i) assume a general role of leadership in the partnership. 

2.5.3. Frequency of Meetings. The Joint Steering Committee shall meet at least two (2) times per year or more or less often as otherwise agreed by
the Parties, but in no event less than once annually and such meetings may be conducted by telephone, videoconference or in person as determined by the Co-Chairpersons. As appropriate, and provided that not
less than two (2) Business Days’ prior written notice has been given to the other Party, other employees of the Parties may attend Joint Steering Committee meetings as observers, but a Party shall not bring a Third Party to a meeting
without the other Party’s prior consent. Each Party may also call for special meetings of the Joint Steering Committee with reasonable prior written notice (it being agreed that at least ten (10) Business Days shall constitute reasonable
notice) to resolve particular matters requested by such Party and within the decision-making responsibility of the Joint Steering Committee. Each Co-Chairperson shall ensure that its Joint Steering Committee members receive adequate notice of such
meetings. 
 2.5.4. Subcommittees. The JSC may establish and disband such subcommittees as deemed necessary by the JSC. Each such subcommittee shall
consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its representatives on written notice to the other Party or to send a substitute
representative to any subcommittee meeting. Each Party’s representatives and any substitute for a representative shall be bound by the obligations of confidentiality set forth in article 8. Except as expressly provided in this Agreement, no
subcommittee shall have the authority to bind the Parties hereunder and each subcommittee shall report to the JSC. 

  
 10/44 








 2.6. Joint Research and Development Committee (the “JRDC”). 

2.6.1. Composition. The JRDC shall be comprised of four (4) named representatives of each Party (or such other number as the Parties may agree) in
addition to each Party’s Alliance Manager who are members ex-officio. Promptly following the Effective Date, each Party shall designate by written notice to the other Party its initial representatives on the JRDC. Each Party may replace one or
more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change. Either Party may, from time to time, invite additional representatives or consultants to attend JSC meetings, subject to such
representative’s and consultant’s written agreement to comply with confidentiality obligations substantially the same as those set forth in article 8. 

2.6.2. Function and Powers of the JRDC. The JRDC responsibilities shall include the following activities: (a) propose for approval by the JSC, the
Development Plan(s), as well as any update, with respect to each Program, and the criteria of success for the Milestones, (b) implement the Preclinical Development activities of the Collaboration; (c) shall take responsibility for the
performance of the Clinical activities for each Program; (d) oversee the implementation of the Development Plan(s) and the Development operational aspects of the Program(s); (e) develop forecasts for Clinical Supply Requirements to enable
the timely preparation of the Manufacturing Plan; (h) oversee clinical and regulatory matters pertaining to Pre-Candidate Product(s), Candidate Product(s) or Products in the Field arising from the Development Plans, and review and approve
protocols, statistical analysis plans, clinical study endpoints, clinical methodology and monitoring requirements for clinical trials of Candidate Product(s) and Product(s) in the Field as contemplated under the Development Plan(s);
(i) evaluate the need and conduct biomarker strategy, (j) establish sub-committees of the JRDC, as appropriate. 
 2.6.3. Frequency of
Meetings. The Joint Research and Development Committee shall meet at least once (1) time per quarter or more or less often as otherwise agreed by the Parties, but in no event less than twice annually and such meetings may be conducted by
telephone, videoconference or in person as determined by the Co-Chairpersons. As appropriate, and provided that not less than two (2) Business Days’ prior written notice has been given to the other Party, other employees of the Parties may
attend Joint Steering Committee meetings as observers, but a Party shall not bring a Third Party to a meeting without the other Party’s prior consent. Each Party may also call for special meetings of the Joint Research and Development Committee
with reasonable prior written notice (it being agreed that at least ten (10) Business Days shall constitute reasonable notice) to resolve particular matters requested by such Party and within the
decision-making responsibility of the Joint Research and Development Committee. Each Co-Chairperson shall ensure that its Joint Research and Development Committee
members receive adequate notice of such meetings. 
 2.6.4. Subcommittees. The JRDC may establish and disband such subcommittees as deemed
necessary by the JRDC. Each such subcommittee shall consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its representatives on written
notice to the other Party or to send a substitute representative to any subcommittee meeting. Each Party’s representatives and any substitute for a representative shall be bound by the obligations of confidentiality set forth in article 8.
Except as expressly provided in this Agreement, no subcommittee shall have the authority to bind the Parties hereunder and each subcommittee shall report to the JRDC. 

  
 11/44 








 2.7. Co-Chairpersons. 

Each Party shall appoint one of its members in each Committee to co-chair such Committee’s meetings (each, a “Co-Chairperson”). The
Co-Chairpersons shall (i) ensure the orderly conduct of the Committee’s meetings, (ii) attend each Committee meeting (either in-person, by videoconference or telephonically), and
(iii) ensure the preparation and issuance of written minutes of each meeting within thirty (30) days thereafter accurately reflecting the discussions and decisions of such meeting. Unless otherwise agreed, the Committee shall have at least
one (1) representative with relevant decision- making authority from each Party such that the Committee is able to effectuate all of its decisions within the scope of its responsibilities. In the event
the Co-Chair from either Party is unable to attend or participate in a Committee meeting, the Party who designated such Co-Chairperson may designate a substitute Co-Chairperson for the meeting in its sole
discretion. 
 2.8. Quorum; Location. 
 Except where a
Party fails to appoint a member or members to the JEC, JSC, JRDC or any subcommittee or fails to participate in meetings of the JEC, JSC, JRDC or any subcommittee, meetings of the JEC, JSC, JRDC and subcommittee, respectively, shall be effective
only if at least one (1) representative of each Party is present or participating. The JEC, JSC, JRDC and subcommittee may meet either (a) in person at either Party’s facilities or at such locations as the Parties may otherwise agree
or (b) by audio or video teleconference; provided that no less than one (1) meeting during each Calendar Year shall be conducted in person. Additional meetings of the JEC, JSC, JRDC and subcommittee may also be held with the consent of
each Party, or as required under this Agreement, and neither Party shall unreasonably withhold its consent to hold such additional meetings. Each Party shall be responsible for all of its own expenses incurred in connection with participating in all
such meetings. 
 2.9. Cooperation. 
 Each Party shall
provide the JSC such information as required under the Development Plan, or reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of activities under the Development Plan. 

2.10. Decisions. 
 Other than as set forth herein, in
order to make any decision required of it hereunder, the Joint Steering Committee and the Joint Executive Committee must have present (in person, by videoconference or telephonically) at least the Co-Chairperson of each Party (or his/her designee
for such meeting). The Parties will endeavor to make decisions where required of the JSC and JEC by consensus of the Co-Chairpersons and only following a unanimous vote, with each Party having one
(1) vote. If a dispute arises which cannot be resolved within the Joint Research and Development Committee or within a Subcommittee, the Co-Chairpersons of either Party may cause such dispute to be referred to the Joint Steering Committee for
resolution. If a dispute arises which cannot be resolved within the Joint Steering Committee, the Co-Chairpersons of either Party may cause such dispute to be referred to the Joint Executive Committee for resolution. Within the Joint Executive
Committee, the Co-Chairperson of each Party shall try to reach a decision by mutual consent with respect to all matters during the Program Term, however in the event of disagreement between the Co-Chairperson, Servier
Co-Chairperson shall have the final say. 

  
 12/44 








 2.11. Exceptions. 

Notwithstanding the foregoing, neither Party in exercising its right to finally resolve a dispute pursuant to Section 2.10 shall have any power to amend,
modify, or waive compliance with the terms of this Agreement. 
 2.12. Authority. 

The JEC, JSC, JRDC and any subcommittee shall have only the powers assigned expressly to it in this article 2 and elsewhere in this Agreement, and shall not
have any power to amend, modify or waive compliance with this Agreement. In furtherance thereof, each Party shall retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated
or vested in the JEC, JSC, JRDC or subcommittee unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. 

2.13. Discontinuation of Participation on a Committee. 

Each Committee shall continue to exist until the first to occur of (a) the Parties mutually agreeing to disband the Committee or (b) early
termination of the Agreement pursuant to article 11. 
 2.14. Interactions Between the Joint Executive Committee, the Joint Steering Committee, the
Joint Research and Development Committee and the Subcommittees. 
 The Parties recognize that while they will establish the JEC, JSC, JRDC and other
Subcommittees for the purposes hereof, each Party maintains internal structures (including its own committees, teams and review boards) that will be involved in administering such Party’s activities under this Agreement. The Parties shall
establish procedures to facilitate communications between the JEC, JSC, JRDC and Subcommittees hereunder and the relevant internal committees, teams or boards within each Party in order to maximize the efficiency of the Parties’ activities
pursuant to this Agreement. 
  

	ARTICLE  3.	DEVELOPMENT ACTIVITIES 

 3.1. Development of UCART19 Product up to Phase 1. 

Cellectis shall be responsible for conducting the part of Development of the UCART19 Product up to and including the end of Phase I, in accordance with
the corresponding Program description set out in Exhibit 1 and with the corresponding Development Plans. 
 3.2. Development of the five additional
Pre-Candidate Products, Candidate Products and Products. 
 (a) Selection of five Targets. At Effective Date, five Targets as in
Exhibit 3 have been selected and agreed by the Parties. 
 (b) [***] after the Effective Date, the JRDC will, [***], define the
corresponding Programs in the Field (a draft of Program description is enclosed in Exhibit 3) to be approved by the JSC. During [***] or for [***] if agreed by both Parties, for the Target(s) on which Cellectis has not started its Development
activities, the JSC may decide to replace said Target(s) initially 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 13/44 








 
selected by another new Target, provided that Cellectis has the right to refuse any proposed new Target. For the sake of clarity, the initial Target that is replaced by a new Target is outside of
the scope of this Agreement and Cellectis remains free to exploit such initial Target. 
 (c) Selection of the Candidate Products.
Cellectis shall be diligent in the development of an In Vitro Data Package for each Pre-Candidate Product. Such development shall start no later than [***] as of the approval date of the corresponding Program
by the JSC, as stated in Section 3.2. (b) above. Upon reception by Servier of the In Vitro Data Package, Servier shall have the opportunity during [***] to raise questions regarding the In Vitro Data Package and the Pre-Candidate Product.
Following that period, Cellectis has [***] to answer to Servier’s questions to Servier’s satisfaction. Then, Servier shall decide within [***] to turn this Pre-Candidate Product into a Candidate
Product (hereinafter the “Candidate Product Selection”).For sake of clarity, Servier has no obligation to turn any Pre-Candidate Product into a Candidate Product and as a consequence has no
obligation to pay the Milestone event “[***]” for a Pre-Candidate Product not turned into a Candidate Product. 

If Servier does not turn a Pre-Candidate Product into a Candidate Product, Servier definitely waives its right under the Candidate Product and its associated
Primary Target and associated Cellectis IP, Servier will have no further right under the Pre-Candidate Product and its associated Primary Target and its associated Cellectis IP. 

(d) Validation of Milestones achievement. For each of the following Milestone events indicated in Section 6.3(a),
““[***]” per Candidated Product” ““[***]” per Candidate Product”, “[***] per Candidate Product” and “[***] per Candidate Product”, Cellectis will develop a corresponding Milestone Data.
Upon reception by Servier of each data package, Servier shall have the opportunity during [***] to raise questions regarding each data package and the Candidate Product(s). Following that period, Cellectis has [***] to answer to Servier’s
questions to Servier’s satisfaction. Then the JSC may decide within [***] to validate or not the achievement of the corresponding Milestone on the basis of the corresponding Milestone Data. 

(e) Right of First Refusal on a Candidate Product. Should Cellectis wish to transfer (whether by way of a license or an assignment or
the like) to a Third Party Candidate Product(s) for which Servier has exercised its Opt-Out Option as per section 3.6(a), Cellectis shall first propose such transfer to Servier who shall have the right to substitute itself to said Third Party and to
execute corresponding agreement with Cellectis, within a period of [***] after having had the opportunity to review the latest data available, at the same terms and conditions than those proposed by Cellectis to said Third Party. 

3.3. Development of the Pre-Candidate Product(s) and Candidate Products up to Phase 1. 

Following identification and selection of each Pre-Candidate Product and Candidate Product, Cellectis shall be responsible for conducting the Development
activities of the corresponding Pre-Candidate Product and Candidate Product up to and including the end of Phase I, in accordance with the corresponding Program description set out in Exhibit 1 for UCART19 Product and as defined by JRDC and
validated by the JSC for the other Pre-Candidate Product and Candidate Product(s) and with the corresponding Development Plan. Cellectis shall prepare the Development Plan for each Pre-Candidate Product and Candidate Product. Cellectis shall
prepare, file and prosecute all regulatory applications useful or necessary to obtain approvals at Cellectis name to develop the Pre-Candidate Product and Candidate Product up to Phase 1 (e.g. Clinical Trial
Application or equivalent), based on the Development Plan as previously 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 14/44 








 
agreed by the JSC. For sake of clarity, for any Development of a Pre-Candidate Product and Candidate Product not initially planned in the Development Plan, the Parties shall meet in order to
define the technical and financial conditions for such additional Development. 
 3.4. Development of Back-up Products and Follow-on Products. 

The JSC may decide, at any time during the Program Term to add a Back-up Product or, at any time during the Term of the Agreement to add a Follow-on Product
in the corresponding Program. Upon such decision of the JSC, the Back-up Product or the Follow-on Product will be considered as a Pre-Candidate Product or Candidate Product and any and all terms and conditions (except the financial ones as stated in
sections 6.2 and 6.3 below) related to a Pre-Candidate Product or Candidate Product provided in the present Agreement will apply to the Back-up Product or the Follow-on Product. 

3.5. Failure to Develop a Product by Servier. 
 Servier
should use Commercially Reasonable Efforts for the Development of any Product after having exercised its Option to License in relation to such Product. However, should Servier decide to discontinue the Development of any Product after having
exercised the Option to License in relation to such Product, then Servier shall promptly inform Cellectis of such situation and Servier shall terminate the Agreement in accordance with section 11.2.4. 

3.6. Opt-Out Option. 
 (a) Servier has a
right to opt-out from any Program in case Servier decides not to pursue such Program (the “Opt-Out Option”) as follows. Servier may exercise its Opt-Out Option within a period of [***] following the presentation by Cellectis to the JRDC of
the corresponding Milestone Data (“Opt-Out Period”), by sending a written notification. In case the Opt-Out Option is exercised despite achievement of the Milestone by Cellectis as reviewed by the JRDC and validated by the JSC, all sums
due for the achievement of such Milestone shall be paid by Servier to Cellectis. 
 (b) Subject to Section 3.2 (e) “Right of
First Refusal on a Candidate Product”, if Servier has exercised its right under the Opt-Out Option, the corresponding Candidate Product is considered as terminated under this Agreement. Consequently, such
Program is considered as terminated and the rights granted by Cellectis to Servier under the corresponding Program shall automatically terminates and Cellectis shall have no further obligations towards Servier with respect to such Candidate Product.
For sake of clarity, dispositions of Section 11.3 shall to apply. 
 (c) At the end of the Opt-Out Period, if Servier has not exercised
its Opt-Out Option, the payment corresponding to the Milestone validated by the JSC is due to Cellectis for the corresponding Candidate Product, and Cellectis shall continue further Development of the Candidate Product in accordance with this
Section 3. 
 3.7. Subcontracting. 
 Cellectis may
engage its Affiliates, and/or Third Party subcontractors (including contract manufacturing organizations or contract research organizations) to perform certain of its obligations under this Agreement. Any Third Party subcontractor to be engaged by
Cellectis to perform Cellectis’ obligations set forth in this Agreement will meet the qualifications typically 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 15/44 








 
required by Cellectis for the performance of work similar in scope and complexity to the subcontracted activity. The activities of any such Third Party subcontractors will be considered
activities of Cellectis under this Agreement. Cellectis will be responsible for ensuring compliance by any such Third Party subcontractors with the terms of this Agreement. In any case in which Cellectis engaged a Third Party subcontractor,
Cellectis will contractually agree to obtain sole ownership or secure a license (with the right to grant sublicenses) of all inventions, data, information developed by such Third Party subcontractor necessary for the Development of Pre-Candidate Product, Candidate Product or Product(s). Cellectis will remain responsible for any breach by a subcontractor of the terms of this Agreement or the applicable subcontractor agreement. 

Cellectis will, and will contractually require that its sub-licensees, subcontractors and Affiliates, if any, use Commercially Reasonable Efforts to conduct
the relevant Development activities in an effort to meet Cellectis’ commitments with respect to such Programs and any development activities. 

3.8. Clinical Trial Activities after Phase 1. 
 After
exercising its Option to License according to Section 4.1, Servier will be sole responsible for further Developing and Commercializing the Product(s). However, Servier may request Cellectis to perform certain Development activities after Phase
1, on behalf of Servier and subject to a separate written agreement that will be negotiated by the Parties in good faith. 
 3.9. Data. 

During the Program Term, Cellectis shall promptly make available to Servier all Data generated by Cellectis and its Affiliates or on their behalf. 

3.10. Non-Compete. 
 During the Term, Cellectis
undertakes not to perform (or have a Third Party performing on Cellectis’s behalf) research on, development on, and/or commercialization of a product directed against a Target that is used for the same purpose than for its use with a Pre-Candidate Product, Candidate Product or Product (“Primary Target”). However, for sake of clarity and based on current knowledge, Cellectis may use the Target if it is not intended to directly
trigger the destruction of tumors or tumor cells by the product but intended to provide specificity or additional functionalities to the product directed against another primary target. In this case, the Target is used necessarily in combination
with another primary target to develop the product. 
 3.11. Right of First Negotiation. 

During the Term, Cellectis has the right to perform internal research activities on the selected Targets for other uses than as Primary Target(s). In the
event Cellectis wishes to grant a license or transfer the outcome of such research activities to a Third Party, Servier will have a right of first negotiation. After Cellectis written notification of the existence of such outcome, Servier shall have
the opportunity, during [***] from the receipt of said notification, to raise questions regarding the outcome. Following that period, Cellectis has [***] to answer to Servier’s questions to Servier’s satisfaction. Then, Servier shall
decide, within [***] from the Cellectis’s answer, if it wishes to exercise its right of first negotiation to obtain a license on such outcome. The Parties will then have [***], from the notification by Servier to exercise its right of first
negotiation, to reach an agreement as to the licensing terms and conditions pertaining to such outcome. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 16/44 









	ARTICLE  4.	GRANT OF RIGHTS TO SERVIER 

 4.1. Exclusive Option to License. 

(a) Cellectis hereby grants to Servier, and Servier accepts, an exclusive option, exercisable according to the conditions set forth in
Section 4.1(b), to obtain, on a Product-by-Product basis, an exclusive license under each Product (the “Option to License”) 

(b) Exercise of the exclusive Option to License. Upon reception by Servier of each Phase 1 Data Package, Servier shall have the
opportunity during [***] to raise questions regarding the Phase 1 Data Package and the Candidate Product. Following that period, Cellectis has [***] to answer to Servier’s questions to Servier’s satisfaction. Then, Servier may, during the
following [***], exercise the Option to License for the corresponding Candidate Product, by sending a written notification to Cellectis. 
 For the
avoidance of doubt, the Parties understand and agree that Option to License will be exclusive, and unless and until Servier exercises its right to the Option to License with respect to any relevant Candidate Product, neither Cellectis nor any of its
Affiliates will have the right to offer or negotiate with any Third Party regarding the grant to such Third Party of any right or license in or to Candidate Product. However, Cellectis shall remain free to use said Candidate Product for its internal
research. 
 (c) Non-exercise of Option to License. In the event Servier fails to notify Cellectis of its election, or elects not to
exercise its Option to License, Servier’s rights to such Candidate Product shall terminate and Cellectis shall have no further obligations towards Servier with respect to such Candidate Product, and Cellectis may independently pursue all
activities related to such Candidate Product and/or license-out the Candidate Product and the associated Cellectis IP , Joint IP and Servier IP to a Third Party. To that end, Servier grants to Cellectis a non-exclusive, sublicensable,
royalty-bearing license on Servier’s IP (the “License to Cellectis”). 
 Notwithstanding the foregoing, in consideration for the License to
Cellectis and for Servier’s financial contribution to the Development of the Candidate Product, Cellectis will pay to Servier the following payments, to the extent that the said Candidate Product is Covered by a Valid Claim of Servier Patents:

  

	 	(i)	If Servier terminates the license with respect to a Candidate Product up to the first Phase I, Cellectis shall pay to Servier [***] of the Net Revenues it receives from a Third Party; 


 

	 	(ii)	If Servier terminates the license between the beginning of first Phase I and Phase Ill of a Candidate Product or Product, Cellectis shall pay to Servier [***] of the Net Revenues it received from a Third Party;


  

	 	(iii)	If Servier terminates the license with respect to a Product from MAA filing of a Product, Cellectis shall pay [***] of Net Revenues for such Product. 


4.2. Servier Rights and Obligations Upon Exercise of Option. 

(a) Exclusive License. Upon Servier’s exercise of its Option to License for a given Product, Cellectis shall grant to Servier, during the
Term, an exclusive worldwide license, with the right to grant sublicenses, under Cellectis IP to Develop, have developed, manufacture, have manufactured and Commercialize said Product in the Field. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 17/44 








 (b) With respect to each Product elected by Servier, through its Option to License, Servier will
assume full responsibility, at its expenses, for the further Development, manufacture and Commercialization of such Product in the Field. 

(c) Servier Diligence. Upon Servier’s exercise of the Option to License for a given Product, Servier will use, and will ensure that its
Affiliates, Sublicensees and subcontractors use Commercially Reasonable Efforts in Developing and Commercializing the corresponding Product in the Targeted Indications and the Targeted Territory, and are in compliance with the Agreement. 

 

	ARTICLE  5.	TRANSFER AND SUPPLY 

 5.1. Cellectis Transfer Cooperation. 

Upon Servier’s exercise of the Option to License, Cellectis will provide Servier with any information, materials and data, Competent Authorities’
approval available to it and reasonably necessary for Servier to continue the Development, Manufacturing and/or Commercialization of the Product, and Cellectis will cooperate with Servier to provide transfer of such information, materials and data
as soon as reasonably practicable after the Option to License is exercised. 
 5.2. Supply of Product. 

Upon exercise of the Option to License with respect to a given Program, and upon Servier’s request, Cellectis shall Manufacture or have Manufactured in
compliance with cGMP the corresponding Products for Servier’s benefit until the end of the Phase II studies to be conducted by Servier, its Affiliates or its Sublicensees, subject to a written supply and quality agreements whose terms and
conditions shall be negotiated in good faith between the Parties within [***] upon exercise of each Option to License. The supply price of the Product (in finished form) shall be at manufacturing costs, incurred by Cellectis, plus [***]. 

Servier may elect at any time before entering into the first Phase II studies (or during the performance of the Phase II studies) to have the manufacture of
the Products transferred by Cellectis or its designee, at Servier’s costs, to a Contract Manufacturing Organization selected by Servier and reasonably acceptable to Cellectis. The Parties will execute a
tri- partite technology transfer agreement between Servier, the Contract Manufacturing Organization and Cellectis, provided that Cellectis will transfer (or will have transferred) to the Contract Manufacturing
Organization the know-how, material and data necessary for the proper manufacturing of the Products. 
  

	ARTICLE  6.	PAYMENTS AND MILESTONES 

 6.1. Upfront Fee. In consideration for the signature of the Agreement,
Servier shall pay Cellectis the non-refundable and non-deductible lump sum payment of two millions and five hundred thousand euros (2,500,000 €), excluding taxes, within [***] of the Effective Date and
receipt of the corresponding invoice. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 18/44 








 6.2. License Fees. Upon exercise of each Option to License for Products pursuant to Section 4.1
herein (except for Backup Products), Servier will pay Cellectis the non- refundable and non-deductible lump sum payment of [***], excluding taxes. 

Upon exercise of each Option to License for Follow-on Products pursuant to Section 4.1 herein, Servier will pay Cellectis the non-refundable and non-deductible lump sum payment of [***], excluding taxes. 
 6.3. Milestone event Payments to
Cellectis. 
 (a) In consideration for the rights granted to Servier under this Agreement Servier will pay to Cellectis for each
Candidate Product, Product, Backup Product or Follow-on Product the following non-refundable milestone payments upon the occurrence of each event as set forth below. No milestone payment will be owed by Servier to Cellectis if the corresponding
event to which such milestone payment relates is not deemed as achieved by the JSC pursuant to Section 3.5. 
  

			
	 Milestone event
	  	Milestone payment (in €)
	 [***]
	  	

 (b) The non-refundable milestones set forth below shall be paid in full for the Candidate Product or the
Product (as applicable). 
 (c) Those milestones set forth below, when already paid for the Candidate Product or the Product, shall not be
paid a second time for the Backup Product. For sake of clarity, the milestones that have not been paid for the Candidate Product or Product shall be paid in full for the Backup Product. 

(d) For Follow-on Products, those milestones shall only be paid at [***] (i.e. the “[***]” milestone shall only be [***]). 

(e) No milestone payment will be owed by Servier to Cellectis if the corresponding event to which such milestone payment relates is not deemed
as achieved by the JSC pursuant to Section 3.5. 
  

			
	 Milestone event
	  	Milestone payment (in €)
	 [***]
	  	

 (f) Milestones already achieved at the Effective Date. 

 

	 	(i)	With respect to UCART19 Product, the Parties hereby acknowledge that the following Milestones have been achieved by Cellectis at the Effective Date: 


 

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	 	•	 	[***] 


  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 19/44 








 Consequently Servier shall pay to Cellectis the sum of [***] excluding taxes, within [***] of
the Effective Date. 
  

	 	(ii)	With respect to the other five additional Programs, the Parties hereby acknowledge that Cellectis has already committed to reserve for Servier 5 additional Targets in the Field. Consequently, Servier shall pay to
Cellectis the sum of [***], excluding taxes, within [***] of the Effective Date. 

 For sake of clarity, within [***] of the
Effective Date, Servier shall pay to Cellectis a total amount not exceeding seven million and five hundred fifty thousand euros (7,550,000€). 

(g) In the event that Servier grants rights relating to Cellectis IP for the Development and/or Commercialization of a Candidate-Product or
Product (including but not limited to a right of first refusal, or a right of first negotiation, or an option) to a Third Party for the territory of the United States of America before the date of exercise of each Option to License pursuant to
section 4.1, on a Candidate Product-by-Candidate Product or Product-by-Product basis, Servier undertakes to pay to Cellectis an amount equal to [***] of all sums received by Servier from such Third Party, for such right, before the date of exercise
of each Option to License and [***] thereafter. 
 6.4. Sales Milestones to Cellectis. 

Servier shall pay the following sales milestones the first time that annual Net Sales of a Product reach the following thresholds: 

 

			
	 First time annual Net sales of a Product reaches
	  	Milestone payment (in €M)
	 [***]
	  	

 6.5. Royalties to Cellectis. 

During the Royalty Term(s), Servier shall pay royalties to Cellectis on annual Net Sales of the Products: 

 

			
	 Aggregate annual Net Sales of the Products
	  	Royalty
	 [***]
	  	

 6.6. Royalty Reductions. 

6.6.1. Joint Patent(s). Notwithstanding the foregoing, should a Product, at any time, be solely Covered by Joint Patent in a given country within the
Territory, then the royalties payable by Servier to Cellectis for such Product in such country shall be reduced by [***] of the amount otherwise payable hereunder (e.g., from [***]) as of the date such situation occurs. 

6.6.2. Competition on the Target. Notwithstanding the foregoing, if there are and as soon as there are, in a given country within the Territory, sales of an
allogeneic CART cell therapy 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 20/44 








 
targeting the same Target as a Product occurring before the First Commercial Sale of a Product, the royalties payable to Cellectis hereunder for the Product in such country shall be reduced by
[***] of the amount otherwise payable hereunder (e.g., from [***]) as of the date of such first sales. 
 6.6.3. Third Party Royalty Payments. If Servier or
any of its Affiliates or sublicensee (i) determines in its good faith judgment with advice from a external legal attorney that it is necessary or advisable to obtain a license from any Third Party in order to make, have made, use, sell, offer
for sale or import any Product and pursuant to such license is required to pay any consideration, in the form of a royalty based on sales of such Product, or (ii) is required by any court of competent jurisdiction to pay damages and/or such
license fees to such a Third Party in order to make, have made, use, sell, offer for sale or import any Product, then Servier shall use commercially reasonable efforts to negotiate a favorable economic license and Servier will be entitled to deduct
up to [***] of such payments (until full reimbursement by Cellectis) from the royalties associated to such Product otherwise payable under Section 6.5 (Royalties to Cellectis), provided however that in a given year, Royalties of Cellectis shall
not be reduced of more than [***] than the initial value stated in 6.5. 
 The foregoing shall be without prejudice to any payment Cellectis has to make to
Third Parties on the basis of intellectual property that: (i) is licensed by Cellectis prior to or as of the Effective Date; (ii) is intellectual property that Cellectis had knowledge of potential infringement from a Third Party prior to
the exercise by Servier of the exclusive Option to License and that Cellectis did not disclose same to Servier in writing at that time at the latest; or (iii) is licensed or acquired by Cellectis after the Effective Date without Servier’s
prior written consent and related to the Product or uses or methods of manufacture thereof (or of its components). 
 6.7. Payment Terms. 

6.7.1. All sums due hereunder to either Servier or Cellectis will be payable in Euros, by bank wire transfer in immediately available funds to such bank
account(s) as the Parties will designate. Each Party will notify the other as to the date and amount of any such wire transfer at least seven (7) days prior to such transfer. 

6.7.2. Except as otherwise set forth herein, all other payments due hereunder will be paid within [***] following receipt of an invoice requesting such
payment. 
 6.7.3. Invoices. All invoices provided to a Party hereunder should include the receiving Party’s bank details, the contact name for
issue resolution and will be marked for the attention of the alliance manager assigned to this Agreement, whose name will be provided by the Parties to each other. 

6.7.4. Late Payment Penalties. Interest shall accrue on any late payment of fees owed to the receiving Party not made on the date such payment is due,
at an annual interest rate equal to the lesser of the Euribor 1 month fixed by the European Central Bank plus three percent (3%) or the highest rate permissible by law, with such interest accruing from the date the payment was originally due to
the receiving Party, and any late payment pursuant to this Section shall be credited first to interest and then to any outstanding fees. This Section shall in no way limit any other rights and remedies available to the Party to whom payment is owed,
whether arising under this Agreement or at law or in equity. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 21/44 








 6.8. Reports and Audits. 

(a) Milestone Payment Reports. After each Option Date, and on a Product-by-Product basis,
Servier shall report each event that triggers a payment to Cellectis pursuant to Section 6.3, within ten (10) business days of the occurrence of such event. Cellectis will then prepare an invoice to Servier for the same, such payment shall
be due within [***] from the invoice date. If no event has been reached, this shall be reported once a year [***] following the 151 of January of each contractual year. 

(b) Sales Payment Reports. After the First Commercial Sale by Servier, its Affiliates or its Subcontractor of a Product requiring the
payments due to Cellectis pursuant to Sections 6.4 and/or 6.5, Servier shall send to Cellectis an annual written reports within [***] following the 1st of January of each contractual year. Such report shall state, for the previous contractual year,
the number and description of each Product sold, by country, the corresponding Net Sales and the calculation of Milestone and royalties due. Concurrently with the sending of such reports, Servier shall pay to Cellectis royalties and/or milestones
due at the rates specified in Sections 6.4 and 6.5. 
 (c) Records; Inspection. Servier shall keep complete, true and accurate books
of account and records for the purpose of determining the royalty amounts or Milestone payment amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of such Party, as the case may be, for at
least [***] following the end of the [***] to which they pertain. Servier shall make such account and records available, on reasonable notice sent by Cellectis, for inspection during business hours by an independent auditor nominated by Cellectis
and reasonably acceptable for Servier, for the purpose of verifying the accuracy of any statement or report given by Servier pursuant to Section 6.8 (a) and (b). The auditor shall be required to keep confidential all information learnt
during any such inspection, and to disclose to Cellectis only such details as may be necessary to report the accuracy of Servier’s statement and/or report. Cellectis shall be responsible for the auditor’s costs, unless the auditor
certifies that there a variation or error producing an increase exceeding five percent (5%) of the royalty amount stated for any period covered by the inspection, then all reasonable costs relating to the inspection for such period and any
unpaid amounts that are discovered shall be paid promptly by Servier, together with interest thereon from the date such were due at the lesser of the legal rate fixed by the European Central Bank plus two percent (2%) or the highest rate
permissible by law, and any pursuant to this Section shall be credited first to interest and then to any outstanding royalties. 
  

	ARTICLE 7.	INTELLECTUAL PROPERTY AND PATENT RIGHTS 

 7.1. Inventions and Intellectual Property Ownership.

 (a) Inventions. Ownership of inventions shall be determined according to the rules in effect at the time of invention in the country
where the invention is made. 
 (b) Sole Inventions. Each Party shall own all inventions, Know-How and other intellectual property, whether
or not patentable, conceived and made solely by its or its Affiliates’ own employees, agents, or independent contractors in the course of conducting its or its Affiliates’ activities under this Agreement, together with all intellectual
property rights therein (“Sole Inventions”). 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 22/44 








 (c) Joint IP shall be co-owned equally by the Parties. Each Party shall have a right of first
refusal to any assignment of its interest into a Joint Patent by a Party (the “Assigning Party”) to any Third Party. Should the Assigning Party wish to assign such Joint Patent to a Third Party, the Assigning Party shall first propose such
assignment to the other Party who shall have the right to substitute itself to said Third Party within a period of [***]. 
 Parties agree to share the
exploitation of the Joint IP as follow: 
  

	 	(i)	Servier shall have the sole right to exploit, directly or indirectly, the Joint IP that covers specifically and solely a Pre-Candidate Product, Candidate Product or Product (the “Product Joint IP”) without any
financial compensation to Cellectis, and Cellectis shall have the right to use such Product Joint IP solely to perform its rights and obligation as contemplated in the Agreement. 


 

	 	(ii)	Cellectis shall have the sole right to exploit and sublicense Joint IP that does not cover specifically and solely a Pre-Candidate Product, Candidate Product or Product (the “Platform Joint IP”) without any
financial compensation to Servier, and Servier shall have the right to use such Platform Joint IP to perform its rights and obligation as contemplated in the Agreement. 


(d) Background IP. Each Party will own all right, title and interest in its Background IP. 

7.2. Patent Prosecution. 
 Cellectis Patent(s). Cellectis
will be responsible, at its own cost for preparing, filing, prosecuting and maintaining all Cellectis Patents and conducting any interferences, re-examinations, reissues and oppositions relating to such Patents. Cellectis shall seek patent
protection on all Cellectis Patents. Cellectis and its Affiliates have the right to cease all activities relating to the preparation, filing, prosecution and/or maintenance of any Patents as provided in this Section 7.2(a) if Cellectis or its
Affiliates question the patentability of such Patents and/or such Patents do not cover Pre-Candidate Product, Candidate Product or Product, in which case Cellectis will promptly inform Servier of such planned cessation and Servier may, upon
providing written notice to Cellectis, at its own choice, either assume responsibility, at Cellectis’ costs for the preparation, filing, prosecution and/or maintenance of such Patents, or rescind this Agreement. 

(a) Servier Patent(s). Servier will be responsible, at its own cost for preparing, filing, prosecuting and maintaining all Patents covering
the Servier Patents and conducting any interferences, re-examinations, reissues and oppositions relating to such Patents. 
 (b) Joint
Patent(s). So long as Servier has not exercised the Option to License as indicated in section 4.1 above (Exercise of the exclusive Option to License), the provision of section 7.2(a) above shall apply. As soon as Servier has exercised the Option to
License as indicated in section 4.1 above (Exercise of the exclusive Option to License), the provision of section 7.2 (b) above shall apply. Should a Party (the “Abandoning Party”), in charge of the prosecution of the Joint IP, decide
not to protect, prosecute or maintain the protection of Joint Patent, such Abandoning Party shall inform the other Party (the “Non-Abandoning Party”) reasonably in advance so that such Non-Abandoning Party may elect to pursue said
protection and/or maintenance of said protection in its own name. In such case, the Non-Abandoning Party shall have full ownership of and title to said Joint Patent. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 23/44 








 7.3. Patent Term Extensions. 

The Parties will cooperate with each other in gaining Patent term extension where applicable to Candidate Product or Products. 

7.4. Defense and Settlement of Third Party Claims. 
 From
the Effective Date and until Servier’s exercise of its Option to License for a given Pre-Candidate Product or Candidate Product, if a Third Party asserts that a patent right or other right owned by it is infringed by the manufacture, use, sale
or importation of the given Pre-Candidate Product or Candidate Product in the Territory by Cellectis, Cellectis shall have the sole right to defend against any such assertions at its sole cost and shall immediately inform Servier of such assertion.

 After Servier has exercised its Option to License for a given Product, if a Third Party asserts that a patent right or other right owned by it is
infringed by the manufacture, use, sale or importation of the given Product in the Territory by Servier, Servier shall have the sole right to defend against any such assertions at its sole cost. Cellectis shall reasonably assist Servier and
cooperate in any such litigation at Servier’s request, and Servier shall reimburse Cellectis any reasonable, documented, out-of-pocket costs incurred in connection therewith. Subject to such control, Cellectis may join any defense and
settlement pursuant to this Section 7.4 (Defense and Settlement of Third Party Claims), with its own counsel at its sole cost. Servier shall seek and reasonably consider Cellectis’ comments before determining the strategy for such matter.
Without limiting the foregoing, Servier shall keep Cellectis advised of all material communications, actual and prospective filings or submissions regarding such action, and shall provide Cellectis copies of and an opportunity to review and comment
on any such communications, filings and submissions. Servier shall not settle or consent to the entry of any judgment in any such action without Cellectis’s prior written consent, not to be unreasonably withheld or delayed. Servier shall keep
Cellectis fully informed of all claims and actions governed by this Section 7.4 (Defense and Settlement of Third Party Claims). In the event Servier becomes engaged in: (i) settlement discussions with a Third Party that has specifically
asserted that a patent right of such Third Party would be infringed by the use, sale or importation of the Pre-Candidate Product or Candidate Product or Product; (ii) settlement discussions of an interference involving a patent corresponding to
a Cellectis Patent; Servier shall keep Cellectis reasonably informed of the status of such discussions; and (b) Servier shall consider in good faith any comments or suggestions of Cellectis. 

7.5. Enforcement. 
 Each Party shall promptly notify the
other Party in writing if it reasonably believes that any Cellectis IP or Joint IP are infringed or misappropriated by a Third Party in the Territory. 

Prior to Servier’s exercise of its Option to License. 

Cellectis shall have the sole right, but not the obligation, to enforce Cellectis IP and Joint IP against any actual, alleged or threatened infringement or
misappropriation by Third Parties in the Territory, at Cellectis’ sole cost. 
 From and after Servier’s exercise of its Option
to License. 
 If a Party has knowledge that a Third Party is making, using, selling a product in the Field in the Territory that infringes or may
infringe a Cellectis IP or a Joint IP, such Party shall promptly notify the other Party in writing of the possible infringement and such notice shall describe in detail the information suggesting the infringement of the Cellectis IP or the Joint IP.


  
 24/44 








 Prior to commencing any action to enforce a Cellectis IP or a Joint IP, the Parties shall diligently enter into
good faith negotiations on the desirability to bring a suit, the Parties to the action and the selection of counsel, and any such matters as the Parties need to discuss. 

If Servier is the Party designated by the Parties to initiate the action (such decision shall be subject, without limitation, to the rights of the Third
Parties owners of Cellectis Patents at the Effective Date), Servier shall have the right, but not the obligation, to enforce Cellectis IP and Joint IP against any actual, alleged or threatened infringement or misappropriation by Third Parties in the
Territory, in the Field and related to a Product, at Servier’s sole costs. In the event Servier elects to bring and prosecute such an action, Cellectis shall reasonably assist Servier and cooperate in any such action at Servier’s request
(and Servier shall reimburse all reasonable, documented, out-of-pocket expenses incurred by Cellectis in connection therewith), and Servier shall seek and reasonably consider Cellectis’s comments before determining the strategy. Without
limiting the foregoing, Servier shall keep Cellectis advised of all material communications, actual and prospective filings or submissions regarding such action, and shall provide Cellectis with copies of and an opportunity to review and comment on
any such material communications, filings and submissions. Servier shall not settle, or consent to any judgment in, any action under this Section 7.5, without Cellectis’s prior written consent, not to be unreasonably withheld or delayed.

 If Cellectis is the Party designated by the Parties to initiate the action Cellectis shall be entitled to bring and prosecute such an action at
Cellectis’ sole cost and Servier will cooperate with Cellectis. If Cellectis elects to bring and prosecute such an action, then Cellectis shall seek and reasonably consider Servier’s comments on strategy. Without limiting the foregoing,
Cellectis shall keep Servier advised of all material communications, actual and prospective filings or submissions regarding such action, and shall provide Servier copies of and an opportunity to review and comment on any such material
communications, filings and submissions. Cellectis shall not settle, or consent to any judgment in, any action under this 7.5, without Servier’s prior written consent, not to be unreasonably withheld or delayed. 

For sake of clarity, nothing in the Agreement shall be understood as affecting or reducing the Cellectis’s right to enforce Cellectis Patents in the
Field and in the Territory. 
 In any case, Servier shall not take any actions which can affect the scope, the validity, the enforceability or otherwise the
Cellectis Patents without the Cellectis’s prior written approval. 
  

	ARTICLE 8.	CONFIDENTIAL INFORMATION 

 8.1. During the term of this Agreement and for a period of [***] after
its termination or expiration, each Party and/or its Affiliates (the “Receiving Party”) undertakes to keep strictly confidential and not to publish or disclose to a Third Party, all the information which is transmitted visually, orally, in
writing, in electronically, or in any and all other manner by the other Party and/or its Affiliates (the “Disclosing Party”) pursuant to and in accordance with this Agreement, and/or relating to this Agreement, each Program, each
Pre-Candidate Product or Candidate Product or Product and intellectual property (the “Confidential Information”) without the prior written consent of Disclosing Party. The Joint IP shall be deemed Confidential Information of both Parties.


  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 25/44 








 8.2. The Receiving Party shall only be entitled to disclose, on a need to know basis for the purpose of
the performance of the Agreement, Confidential Information to its directors, employees, Affiliates, consultants, sublicensees, licensors, subcontractors, or to a potential investor in the Receiving Party or to a potential acquirer of all or
substantially all of the assets of the business to which this Agreement pertains (collectively, the “Authorized Recipients”); 
 provided that
(i) the Receiving Party has previously informed the Disclosing Party of its intent to communicate Confidential Information and keep available upon the Disclosing Party’s request the content of such communication, and (ii) the
Receiving Party has taken into good faith consideration the comments made by the Disclosing Party, and (iii) the Receiving Party considers in good faith the Disclosing Party’s request to be communicated the name of the potential
investor(s) or potential acquirer(s), and (iv) the Receiving Party has bound such Authorized Recipients by confidentiality and restricted use obligations at least as stringent than those set forth in this Agreement. The Receiving Party shall be
responsible towards the Disclosing Party for any breach by its Authorized Recipients of any such confidentiality and restricted use obligations. 
 8.3.
Notwithstanding Article 8.1, the Receiving Party may use or disclose those information to the extend it can demonstrate, by clear and convincing evidence, that such information: 

(a) at the time of disclosure or acquisition is generally available to the public, or after the time of disclosure or acquisition is generally
available to the public through no wrongful act or omission of the Receiving Party and its Authorized Recipients, or 
 (b) was in the
lawful possession and at the free disposal of the Receiving Party prior to disclosure by the Disclosing Party, as evidenced by written records then in the possession of the Receiving Party, or 

(c) is rightfully made available to the Receiving Party by third parties not bound by confidentiality or restricted use obligations, or 

(d) is independently developed by the Receiving Party without use of the Material and information imparted by the Disclosing Party, or 

(e) is disclosed by the Receiving Party in order to comply with the requirements of applicable law, governmental regulation or definitive
court order, provided that the Receiving Party shall first notify the Disclosing Party of such required disclosure and of each Confidential Information concerned and shall limit such disclosure as far as possible under applicable law. Such
disclosure shall, however, not relieve the Receiving Party of its other obligations contained herein. 
 8.4. Upon termination of this Agreement, the
Receiving Party will return or destroy all documents or other media containing Confidential Information of the Disclosing Party, provided however that the Receiving Party may retain one copy in its confidential files for the sole purpose of
verifying its obligations hereunder. 
 8.5. Remedies. Money damages will not be an adequate remedy if this Article 8 is breached and, therefore,
either Party may, in addition to any other legal or equitable remedies, seek an injunction or other equitable relief against such breach or threatened breach without the necessity of posting any bond or surety. 

  
 26/44 








 8.6. Publications. Prior to any publication in relation to the performance of the Programs, the publishing
Party agrees to provide the other Party with a copy of the paper or proposal for publication or for any other public disclosure at least thirty (30) days prior to its submission for publication or public disclosure. The other Party may review
the manuscript solely in order to: 
  

	 	•	 	ascertain whether its Confidential Information would be disclosed by the publication; and 

  

	 	•	 	identify results that are potentially patentable technology so that appropriate steps may be taken to protect such technology, pursuant to Section 7. 


The non-publishing Party agrees to hold such advance copies of any papers or proposals for publication in confidence. The non-publishing Party will provide
comments, if any, within fifteen (15) days of receipt of paper or abstract. If the non-publishing Party decides, according to Section 7, that a patent application should be filed, the publication or presentation may, at the non-publishing
Party’s request, be delayed an additional sixty (60) days or until a patent application is filed, whichever is sooner. 
 Authorships of any
publications will accurately reflect respective contributions made by the Parties. 
  

	ARTICLE 9.	REPRESENTATIONS; WARRANTIES AND COVENANTS 

 9.1. Representations and Warranties of both Parties.
Each Party represents and warrants to the other Party, at the Effective Date, that: 
  

	 	(i)	such Party is duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the
provisions hereof; 

  

	 	(ii)	this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation, enforceable against it in accordance with the terms hereof, subject to (a) the
effect of applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the rights of creditors and (b) the effect or availability of rules of law governing specific performance, injunctive relief or other
equitable remedies (regardless of whether any such remedy is considered in a proceeding at law or in equity); 

  

	 	(iii)	the execution and delivery of this Agreement by such Party do not, and the performance of this Agreement by such Party, including the grant of rights to the other Party pursuant to this Agreement, will not:
(a) conflict with, or result in any violation of or default under, any agreement, instrument or understanding, oral or written, to which it or any Affiliate is a party or by which it or any Affiliate is bound; (b) conflict with any rights
granted by such Party to any other Third Party or breach any obligation that such Party has to any Third Party; or (c) violate any provision of any applicable law; and 


  
 27/44 








 9.2. Representations and Warranties of Cellectis. 

Cellectis hereby represents that, at the Effective Date: 

9.2.1. Cellectis has the right to grant the rights granted to Servier under this Agreement, and no rights granted to Servier pursuant to this Agreement are in
violation of any agreement between Cellectis or any of its Affiliates and any Third Party; 
 9.2.2. As of the Effective Date, it has sufficient legal
and/or beneficial title and ownership under the Cellectis Patents and Licensed Cellectis Know-How to grant the licenses to the other Party as purported to be granted pursuant to this Agreement; 

9.2.3. None of Cellectis or its Affiliates, or, to the knowledge of Cellectis, any Third Party acting by or on behalf of Cellectis or any of its Affiliates in
connection with the research, development or manufacture of the Pre-Candidate Product, Candidate Product or Product has been debarred or is subject to debarment; 

9.2.4. Cellectis Controls the Cellectis Patents listed on the Cellectis Patents, free of any liens. The Cellectis Patents in the Territory listed on the
Exhibit 2 constitute a true and complete list of all Patents Controlled by Cellectis or its Affiliates in the Territory relating to the Pre-Candidate Product, Candidate Product or Product in the Territory; 

9.2.5. [***] 
 9.2.6. [***] 

9.2.7. [***] 
 9.2.8. [***] 

9.2.9. [***] 
 9.2.10. [***] 

9.2.11. [***] 
 Cellectis undertakes to reiterate the above
representations and warranties at the time of exercise by Servier of each Option to License for a given Candidate Product. 
 9.3. Cellectis Covenants.

 Cellectis shall [***] to maintain any existing agreement with Third Party(ies), to the extent the rights and licenses granted to Cellectis thereunder
are sublicensed to Servier hereunder, and shall not modify, amend, terminate or breach those Third Party(ies) agreement, if such modification, amendment, termination or breach would adversely affect Servier’s rights under this Agreement (after
taking into account any period(s) permitted to cure alleged breaches). 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 28/44 








 9.4. Mutual Disclaimer of Warranties. 

Except as expressly provided in this Agreement, neither Party makes any warranty of any kind either express or implied relating to the Patents, Know-How,
Products, Pre-Candidate Products, Candidate Products, processes used in the Development of the Pre-Candidate Product, Candidate Product or Products, including without limitation any warranty regarding their use, safety, efficacy, or performance, any
warranty of merchantability or any warranty for fitness for any particular purpose or a warranty or representation that anything made, used, sold, or otherwise disposed of under the license granted in this Agreement is or will be free from
infringement of patents, copyrights, and other rights of Third Parties or any other express or implied legal or contractual warranty. 
  

	ARTICLE 10.	INDEMNIFICATION; INSURANCE 

 10.1. Indemnification by Servier. 

Servier will indemnify, defend and hold harmless Cellectis, and its Affiliates, and their respective directors, officers, employees, licensees, and agents,
from and against any and all liabilities, damages, losses, claims, costs and expenses including, but not limited to, the reasonable fees of attorneys and other professionals (collectively “Losses”), arising out of or resulting from any and
all Third Party Claims based upon: 
  

	 	(i)	[***] 

  

	 	(ii)	[***] 

 [***] 

10.2. Indemnification by Cellectis. 
 Cellectis will
indemnify, defend and hold harmless Servier and its Affiliates, and their respective directors, officers, employees and agents, from and against any and all Losses, arising out of or resulting from any and all Third Party Claims based upon: 

 

	 	(i)	[***] 

  

	 	(ii)	[***] 

 [***] 

10.3. Procedure. 
 In the event that any person or entity
(an “Indemnitee”) entitled to indemnification under this Agreement is seeking such indemnification, such Indemnitee will: (a) inform, in writing, the indemnifying Party of the Claim as soon as reasonably practicable after such
Indemnitee receives notice of such Claim; (b) permit the indemnifying Party to assume direction and control of the defense of the Claim (including the sole right to settle it at the sole discretion of the indemnifying Party; provided that such
settlement does not impose any obligation on, or otherwise adversely affect, the Indemnitee or other Party); (c) cooperate as requested (at the expense of the indemnifying Party) in the defense of the Claim; and (d) undertake all
reasonable steps to mitigate any loss, damage or expense with respect to the Claim(s). Notwithstanding the 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 29/44 








 
foregoing, the Indemnitee may retain separate co-counsel reasonably acceptable to the indemnifying Party at its sole cost and expense and participate in the defense of the applicable Claim for
which the indemnifying Party has assumed control. 
 10.4. In no event shall either Party be liable to the other Party for loss of profits, special,
indirect, incidental, punitive or consequential damages arising out of this Agreement or the transactions contemplated by this Agreement. 
 10.5.
Insurance. 
 Each Party will maintain, at its cost, as of the Effective Date and during the Term thereafter, adequate insurance against liability and
other risks associated with its activities contemplated by this Agreement, including but not limited to its clinical trials and its indemnification obligations herein, in such amounts and on such terms as are customary for prudent practices in the
pharmaceutical industry for the activities to be conducted by it under this Agreement. 
  

	ARTICLE 11.	TERM AND TERMINATION 

 11.1. Term. 

This Agreement will become effective as of the Effective Date and, unless earlier terminated pursuant to the provisions of the Sections 11.2, or 12.2.3s, will
expire upon the last sales of Product. Upon expiration of the Royalty Term with respect to a Licensed Product, the licenses granted by Cellectis to Servier under this Agreement with respect to such Product shall remain in effect as granted in
accordance with this Agreement but become fully paid-up, royalty-free licenses until term or termination of this Agreement. 
 11.2. Termination.

 Notwithstanding anything in this Agreement or elsewhere to the contrary, this Agreement may be terminated as follows: 

11.2.1. Material Breach. Either Party (the “Non-Breaching Party”) may, without prejudice to any other remedies available to it at law,
terminate this Agreement in its entirety in the event the other Party (the “Breaching Party”) will have committed a material breach and such material breach will have continued and/or remained uncured for ninety (90) days (except in
the case of a failure to make any payment due under the terms of this Agreement, in which case such failure to pay must be cured within thirty (30) days), after written notice thereof was provided to the Breaching Party by the Non-Breaching
Party. Any such termination will become effective at the end of such ninety (90) day period (or, in the case of a failure to make a payment, at the end of such thirty (30) day period), unless the Breaching Party has cured any such material
breach prior to the expiration of such ninety (90) day period or thirty (30) day period, as the case may be or (ii) unless the Breaching Party notifies the other Party within such sixty (60) day period that it disagrees in good
faith with such asserted basis for termination, this Agreement shall not terminate unless and until the matter has been finally resolved in accordance with Section 12.2 (Dispute Resolution) and the arbitration award rendered specifies that the
non-breaching Party shall have the right to terminate this Agreement based on such asserted breach. The right of either Party to terminate this Agreement as provided in this Section 11.2.1 will not be affected in any way by such Party’s
waiver or failure to take action with respect to any previous default. 

  
 30/44 








 11.2.2. Mutual Consent. This Agreement may be terminated by the mutual written consent of the Parties.

 11.2.3. Termination if Option to License is not exercised by Servier. This Agreement shall immediately and automatically terminate in its entirety
upon expiration of the last Option to License period in the event Servier has not exercised any of the Option to License in accordance with Section 4.1 (Exclusive Option to License) prior to such expiration. 

11.2.4. Termination for convenience by Servier 
 Servier
shall have the right at its sole discretion and without any liability of any kind on the basis of such termination, to terminate this Agreement only with respect to a given Pre-Candidate Product, Candidate
Product or Product or totally at any time upon three (3) month’s prior written notice to Cellectis. 
 11.2.5. Termination for Safety Reasons
by Servier 
 Servier may terminate this Agreement any time for safety reasons relating to the Pre-Candidate
Product, Candidate Product or Products. 
 11.2.6. Termination for Insolvency. 

Either Party may terminate this Agreement if, at any time, the other Party will file in any court or agency pursuant to any statute or regulation of any state
or country, a petition in bankruptcy or insolvency or for the appointment of a receiver or trustee of the Party or of substantially all of its assets, or if the other Party proposes a written agreement of composition or extension of substantially
all of its debts, or if the other Party will be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition will not be dismissed within ninety (90) days after the filing thereof, or if the other Party
will propose or be a party to any dissolution or liquidation, or if the other Party will make an assignment of substantially all of its assets for the benefit of creditors. 

Upon the bankruptcy of any Party, the non-bankrupt Party will further be entitled to a complete duplicate of, or complete access to, any such intellectual
property, and such, if not already in its possession, will be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement. 

11.3. Effects of Expiration or Termination. 
 In the
event of any termination of this Agreement by Cellectis on the basis of either a Material Breach by Servier (section 11.2.1) or insolvency of Servier (section 11.2.6) or by Servier on the basis of non-exercise of the Option to License (section
11.2.3), or for convenience (section 11.2.4), or for safety reasons (section 11.2.5) or by the Parties upon mutual consent (section 11.2.2), or in case of exercise of the Opt-Out Option (Section 3.7): 

 

	 	(i)	Servier will return to Cellectis or destroy (and certify such destruction to Cellectis) all Cellectis Confidential Information (provided that Servier shall be entitled to retain one (1) copy for archival and
compliance purposes, and as required by applicable Law or regulatory requirement); 


  
 31/44 









	 	(ii)	Servier will use reasonable efforts to, to the extent permitted by applicable law and requested by Cellectis, assign any contracts related to the Pre-Candidate Products, Candidate Products or Products in the Territory
to Cellectis or its designee (including by requesting and using good-faith efforts to obtain any required consents); 

  

	 	(iii)	the Parties shall transition responsibility for Commercialization, Development and, if applicable, Manufacture of the Pre-Candidate Product(s), Candidate Product(s) or Product(s) to Cellectis in accordance with
Section 11.6 (Transition Period); 

  

	 	(iv)	the Parties shall cooperate to promptly transition sole responsibility for the prosecution, maintenance and enforcement in the Territory of Servier IP to Cellectis; 


 

	 	(v)	Cellectis shall have the right to reacquire some or all of the inventory of the Pre-Candidate Product(s), Candidate Product(s) or Product(s), as requested by Cellectis, in possession of Servier and its Affiliates and,
if 

 Cellectis so reacquires inventory, shall reimburse Servier the price paid by it for such inventory; 

 

	 	(vi)	the Parties shall cooperate to promptly transfer ownership of all regulatory filings and regulatory approvals (including any such filings and approvals related to manufacturing), and responsibility for regulatory
communication held by Servier in the Territory to Cellectis; 

  

	 	(vii)	all sublicenses granted by Servier shall terminate; 

  

	 	(viii)	Servier will assign to Cellectis the Servier’s interest in the Product Joint IP under terms and conditions to be agreed upon by the Parties. Servier will assign to Cellectis, without any financial compensation, the
Servier’s interest in the Platform Joint IP. 

  

	 	(ix)	Subject to section 11.3(viii) above, Servier will grant Cellectis a royalty-bearing, non-exclusive, sublicensable license under Servier IP that is necessary to further Develop,
Manufacture and Commercialize the Pre-Candidate Product, Candidate Product or Product(s) in the Territory in the Field. 

  

	 	(x)	Cellectis shall have the right to control all recalls of the Product in the Territory, and in each case Servier shall provide any reasonable assistance requested by Cellectis in connection therewith; and


  

	 	(xi)	at Cellectis’s request, the Parties will discuss in good faith the wind-down or transfer to Cellectis of any ongoing clinical trials for the Candidate Products or Products conducted by or on behalf of Servier or
its Affiliates; provided that Cellectis shall bear any expenses incurred in connection with any such transfer except in the event of termination by Cellectis pursuant to Section 11.2.1 (Termination for Material Breach).



  
 32/44 








 In the event that the Parties are not permitted to transfer regulatory filings or regulatory approvals under
clause (vi) above pursuant to applicable laws, the Parties shall cooperate to establish a right of access and reference to such filings and approvals for Cellectis, and Servier shall maintain such filings and approvals, and take any actions
reasonably requested by Cellectis with respect thereto, and thereafter Servier shall transfer ownership of all such regulatory filings and regulatory approvals to Cellectis or its designee as and when it becomes permissible to do so. Cellectis shall
reimburse Servier its reasonable, documented, out-of-pocket costs incurred as necessary for such maintenance and to perform such requested actions. 

11.4. Consequences of a breach of the Non-Compete obligation by Cellectis 

In the event of a breach by Cellectis of the non-compete provision mentioned in section 3.9 above, then as of the date of the breach by Cellectis,
Servier’s obligations as per the Agreement shall be modified as follows: 
  

	 	(i)	Servier shall be relieved from the payment of the Milestones mentioned in sections 6.3 and 6.4 not already paid by Servier; and 

  

	 	(ii)	the level of royalties due to Cellectis mentioned in section 6.5 above shall be reduced by [***]; and 

  

	 	(iii)	the level of the Net Revenues to be paid by Cellectis to Servier on the basis of section 4.1 (c) (i), (ii) and/or (iii) shall be [***] and shall also apply mutadis mutandis to the sales by Cellectis of
the competing product; and 

  

	 	(iv)	notwithstanding any section to the contrary in this Agreement, Servier shall no longer have any obligation to provide information to Cellectis in relation to the Products (except as provided by applicable laws and in
relation to safety issues); and 

  

	 	(v)	notwithstanding any section to the contrary in this Agreement, Servier shall no longer have any obligation to use Commercially Reasonable Efforts to Develop and/or commercialize the Product(s). 


11.5. Accrued Rights and Obligations; Survival. 

Termination or expiration of this Agreement for any reason will be without prejudice to any rights that will have accrued to the benefit of any Party prior to
such termination, relinquishment or expiration. Such termination, relinquishment or expiration will not relieve any Party from obligations which are expressly indicated under this Section 11.6 to survive termination or expiration of this
Agreement. 
 Survival. The provisions of Sections 8, 10, 11.3 and 11.6 will survive the expiration or any termination of this Agreement for any reason, in
accordance with their respective terms and conditions, and for the respective duration stated therein, and where no duration is stated, will survive indefinitely. In addition, any Section that is referred to in the above listed Sections shall
survive solely for the interpretation or enforcement of the latters. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 33/44 








 11.6. Transition Period. 

In the event of any termination of this Agreement by Cellectis on the basis of either a Material Breach by Servier (section 11.2.1) or insolvency of Servier
(section 11.2.7) or by Servier on the basis of nonexercise of the Option to License (section 11.2.3), or for convenience (section 11.2.4), or for safety reasons (section 11.2.5) or by the Parties upon mutual consent (section 11.2.2), or in case of
exercise of the Opt-Out Option (Section 3.7), upon Cellectis’s reasonable request, during the three (3) month period following provision of notice of termination (or, in each case, for such shorter period as Cellectis shall reasonably
request) (the “Transition Period”), the Parties shall cooperate to transition the Development (including any ongoing trials, to the extent permitted by law) and Commercialization of, regulatory responsibility for, and, if
applicable, manufacture of, the Product in the Field in the Territory from Servier to Cellectis. Servier shall take all actions reasonably requested by Cellectis to facilitate such transition, and the Parties shall conduct such transition
expeditiously and as reasonably necessary to minimize disruption in the Development and Commercialization of the Product(s) in the Territory. The Parties shall each be responsible for their own costs incurred in accordance with this Section. 

 

	ARTICLE 12.	CHANGE OF CONTROL 

 12.1. Change of Control. Cellectis shall give Servier written notice within
five (5) days after the public announcement or disclosure of any proposed Change of Control of Cellectis. Upon such notice, Servier shall have the right to buy-out Cellectis’s interest in the Pre-Candidate Products, Candidate Products or
Product(s) hereunder pursuant to the section 12.2 below (Buy-Out). 
 12.2. Buy-Out. Cellectis will notify Servier with [***] after the occurrence of
a Change of Control. If Servier exercises its right to buy-out Cellectis’s interest, Servier will provide written notice to Cellectis (a “Buyout Notice”) within [***] following the Change of Control. Within [***] following
Servier’s provision of the Buyout Notice, the Parties will meet and negotiate the amount of the payment from Servier to Cellectis for the buy-out of Cellectis’s interest in the Pre-Candidate Products, Candidate Products or Product(s) (the
“Buyout Payment”). 
 12.2.1. If the Parties agree on the amount of the Buyout Payment within such [***], then Servier will have [***] to
determine whether to proceed with the buy-out at such price. If Servier elects to proceed with the buy-out at the agreed Buyout Payment, then it will provide written notice thereof to Cellectis (or its successor) and, this Agreement will terminate
[***] after delivery of such written notice, Servier will pay the applicable Buyout Payment to Cellectis (or its successor) within such [***]. 
 12.2.2. If
the Parties fail to agree on an amount of a Buyout Payment within [***] following the provision of the Buyout Notice, then within [***] thereafter each Party will select and pay at its costs one (1) Third Party valuator (such valuators shall be
from top-tier, internationally-recognized investment banks or accounting firms) with relevant expertise to determine the appropriate amount for the Buyout Payment. Each of the Parties will provide to such valuators such information as it deems
pertinent and any information requested by such valuators. Such selected valuators will promptly (and in any event within [***] after the selection of such valuators) determine their respective valuation of the Buyout Payment amount and provide
notice of such amount (and underlying assumptions and methodology) to each of the Parties. If the amount of the Buyout Payment estimated by one valuator is equal to or less than one hundred twenty percent (120%) of the amount of the Buyout
Payment estimated by the other valuator, then the Buyout Payment shall be equal to the average of the amount proposed by the valuators. If the amount of the Buyout Payment estimated by one valuator is greater than one hundred twenty percent
(120%) of the amount of the Buyout Payment estimated by the other 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 34/44 








 
valuator, then the Parties will mutually agree upon a third valuator. In such event, the Buyout Payment determined by the third valuator shall be the Buyout Payment (provided, that the Buyout
Payment shall be capped at the amount of the higher of the Buyout Payments determined by the prior two valuators). 
 12.2.3. After determination of the
Buyout Payment pursuant to Section 12.2.1 or 12.2.2 above, as applicable, Servier will have [***] to determine whether to proceed with the buy-out at such price. If Servier elects to proceed with the buy-out at the agreed Buyout Payment, then
it will provide written notice thereof to Cellectis (or its successor) and this Agreement will terminate [***] after delivery of such written notice, Servier will pay the applicable Buyout Payment to Cellectis (or its successor) within such [***].

  

	ARTICLE 13.	MISCELLANEOUS 

 13.1. Public Announcements 

Except as required by applicable laws or the rules of any stock exchange, neither Party will make any public announcement of any information regarding this
Agreement or any activities under this Agreement without the prior written approval of the other Party, which approval will not be unreasonably withheld or delayed. Each Party will submit to the other Party any proposed announcements at least thirty
(30) days prior to the intended date of publication of such announcement to permit review and approval. Once any statement is approved for disclosure by the Parties or information is otherwise made public in accordance with the preceding
sentence, either Party may make a subsequent public disclosure of the specific contents of such statement without further approval of the other Party. 

13.2. Dispute Resolution. 
 Any dispute, controversy,
difference or claim which may arise between the Parties out of or in relation to or in connection with this Agreement (including arising out of or relating to the validity, construction, interpretation, enforceability, breach, performance,
application or termination of this Agreement) shall be settled by binding arbitration in accordance with the provisions of this Section 13.2 (Arbitration): 
  

	 	•	 	The arbitration shall be conducted in Paris, France. 

  

	 	•	 	The arbitration shall be conducted in accordance with the Rules of Arbitration promulgated by the ‘Centre de Mediation et d’Arbitrage de Paris -CMAP’ then in effect (the “Arbitration
Rules”). 

  

	 	•	 	There shall be three (3) arbitrators, of whom one (1) shall be appointed by each of the Parties and the third shall be appointed by the first two (2) arbitrators and shall serve as chair arbitrator. If
either Party fails to appoint its arbitrator or the arbitrators appointed by the Parties fail to appoint the chair arbitrator within the time period set forth in the Arbitration Rules, such arbitrators will be appointed in accordance with the
Arbitration Rules. 

  

	 	•	 	The proceedings shall be conducted in French, and the arbitrators shall be conversant with and have a thorough command of the French language. 


  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 35/44 








 13.3. Governing Law. 

This Agreement and any dispute arising from the performance or breach hereof will be governed by and construed and enforced in accordance with the laws of
France. 
 13.4. Assignment. 
 This Agreement will not
be assignable by either Party to any Third Party without the written consent of the other Party hereto. Notwithstanding the foregoing, Cellectis may assign this Agreement, without the consent of the other Party, to an Affiliate or to an entity that
acquires all or substantially all of the business or assets of Cellectis to which this Agreement pertains (whether by merger, reorganization, acquisition, sale or otherwise). Any assignment in violation of this provision is void and without effect.

 13.5. Binding Agreement. 
 This Agreement, and the
terms and conditions hereof, will be binding upon and will inure to the benefit of the Parties and their respective successors, heirs, administrators and permitted assigns. 

13.6. Force Majeure. 
 No Party will be held liable or
responsible to the other Party nor be deemed to be in default under, or in breach of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation of this Agreement when such failure or delay is due to force
majeure, and without the fault or negligence of the Party so failing or delaying. For purposes of this Agreement, “force majeure” is defined as causes beyond the control of the Party, including, without limitation, acts of God; laws of any
government; war; civil commotion; destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; labor disturbances; epidemic; and failure of public utilities or common carriers. In the event of force majeure,
Cellectis or Servier, as the case may be, will immediately notify the other Party of such inability and of the period for which such inability is expected to continue. The Party giving such notice will thereupon be excused from such of its
obligations under this Agreement as it is thereby disabled from performing for so long as such Party is so disabled, up to a maximum of ninety (90) days, after which time the Party not affected by the force majeure may terminate this Agreement.
To the extent possible, each Party will use reasonable efforts to minimize the duration of any force majeure. 
 13.7. Notices. 

Any notice or request required or permitted to be given under or in connection with this Agreement will be deemed to have been sufficiently given if in
writing and personally delivered or sent by certified mail (return receipt requested), facsimile transmission (receipt verified), or overnight express courier service (signature required), prepaid, to the Party for which such notice is intended, at
the address set forth for such Party below: 
 If to Cellectis: 

8, rue de Ia Croix Jarry 
 75013 Paris Cedex 

France 
 Attention: Chief Executive Officer 

With a copy to: 
 Attention: VP Business Development 

  
 36/44 








 If to Servier: 
 Les
Laboratoires Servier 
 50 rue Carnot 
 92284 Suresnes Cedex

 France 
 Attention: Alliance Management Director &
US Licenses 
 [***] 
 With a copy to: 

Attention: Director Contract Department 
 Les Laboratoires Servier

 50 rue Carnot 
 92284 Suresnes Cedex 

France 
 or to such other address for such Party as it will have
specified by like notice to the other Parties, provided that notices of a change of address will be effective only upon receipt thereof. If delivered personally or by facsimile transmission, the date of delivery will be deemed to be the date on
which such notice or request was given. If sent by overnight express courier service, the date of delivery will be deemed to be the next business day after such notice or request was deposited with such service. If sent by certified mail, the date
of delivery will be deemed to be the third (3rd) day after such notice or request was deposited with the postal se13.8 Waiver. Neither Party may waive or release any of its rights or
interests in this Agreement except in writing. The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar
subsequent failure to perform any such term or condition. No waiver by either Party of any condition or term in any one or more instances will be construed as a continuing waiver of such condition or term or of another condition or term. 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 37/44 








 13.8. Severability. 

If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the Parties will negotiate in good faith a valid, legal and
enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions hereof will remain in full force and effect in such jurisdiction and will be liberally construed in order to carry out the
intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability will not affect the validity, legality or enforceability of such provision in any other jurisdiction. 

13.9. Entire Agreement. 
 This Agreement, including the
schedules and exhibits hereto, sets forth all the covenants, promises, agreements, appendices, warranties, representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements and
understandings between the Parties relating to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties relating to the subject
matter hereof other than as set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement will be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of
the Parties. 
 13.10. Independent Contractors. 

Nothing herein will be construed to create any relationship of employer and employee, agent and principal, partnership or joint venture between the Parties.
Each Party is an independent contractor. Neither Party will assume, either directly or indirectly, any liability of or for the other Party. Neither Party will have the authority to bind or obligate the other Party and neither Party will represent
that it has such authority. 
 13.11. Headings. 

Headings used herein are for convenience only and will not in any way affect the construction of or be taken into consideration in interpreting this
Agreement. 
 13.12. Construction of Agreement. 
 The
terms and provisions of this Agreement represent the results of negotiations between the Parties and their representatives, each of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion,
whether legal, economic or otherwise. Accordingly, the terms and provisions of this Agreement will be interpreted and construed in accordance with their usual and customary meanings, and each of the Parties hereto hereby waives the application in
connection with the interpretation and construction of this Agreement of any rule of law to the effect that ambiguous or conflicting terms or provisions contained in this Agreement will be interpreted or construed against the Party whose attorney
prepared the executed draft or any earlier draft of this Agreement. 
 13.13. Counterparts. 

This Agreement may be signed in counterparts, each and every one of which will be deemed an original, notwithstanding variations in format or file designation
which may result from the electronic transmission, storage and printing of copies of this Agreement from separate computers or printers. Facsimile signatures will be treated as original signatures. 

  
 38/44 








 IN WITNESS WHEREOF, the Parties have caused this Product Development, Option, License and
Commercialization Agreement to be executed by their duly authorized representatives. 
 Made in Suresnes, on February 17, 2014 

 

									
	For Cellectis SA,				For Les Laboratoires Servier,
					
	By:		  
				By:		  

	Name:		Andre CHOULIKA				Name:		Christian BAZANTAY
	Title:		Chief Executive Officer				Title:		Proxy
					
							By:		  

							Name:		Pascal TOUCHON
							Title:		Proxy
				
	For Institut de Recherche Internationales Servier						
					
	By:		  
						
	Name:		Dr Emmanuel CANET						
	Title:		President of R&D						


  
 39/44 








 Exhibit 1 

[***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 40/44 








 132965/MG/CP 

EXHIBIT 1A 
 [***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 41/44 








 132965/MG/CP 

EXHIBIT 1B 
 [***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 42/44 








 132965/MG/CP 

Exhibit 2 
 [***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 43/44 








 132965/MG/CP 

Exhibit 3 
 [***] 

  
 [***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION 


  
 44/44